- Home
- RQI vs AUPH Comparison
RQI vs AUPH Comparison
Compare RQI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RQI
- AUPH
- Stock Information
- Founded
- RQI 2002
- AUPH 1993
- Country
- RQI United States
- AUPH Canada
- Employees
- RQI N/A
- AUPH N/A
- Industry
- RQI Trusts Except Educational Religious and Charitable
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- RQI Finance
- AUPH Health Care
- Exchange
- RQI Nasdaq
- AUPH Nasdaq
- Market Cap
- RQI 1.7B
- AUPH 1.4B
- IPO Year
- RQI N/A
- AUPH 1999
- Fundamental
- Price
- RQI $12.64
- AUPH $12.40
- Analyst Decision
- RQI
- AUPH Strong Buy
- Analyst Count
- RQI 0
- AUPH 4
- Target Price
- RQI N/A
- AUPH $12.25
- AVG Volume (30 Days)
- RQI 432.6K
- AUPH 1.8M
- Earning Date
- RQI 01-01-0001
- AUPH 07-31-2025
- Dividend Yield
- RQI 8.20%
- AUPH N/A
- EPS Growth
- RQI N/A
- AUPH N/A
- EPS
- RQI N/A
- AUPH 0.42
- Revenue
- RQI N/A
- AUPH $260,111,000.00
- Revenue This Year
- RQI N/A
- AUPH $16.92
- Revenue Next Year
- RQI N/A
- AUPH $14.29
- P/E Ratio
- RQI N/A
- AUPH $29.81
- Revenue Growth
- RQI N/A
- AUPH 25.59
- 52 Week Low
- RQI $9.17
- AUPH $6.42
- 52 Week High
- RQI $12.64
- AUPH $12.82
- Technical
- Relative Strength Index (RSI)
- RQI 60.67
- AUPH 66.76
- Support Level
- RQI $12.32
- AUPH $11.57
- Resistance Level
- RQI $12.59
- AUPH $12.46
- Average True Range (ATR)
- RQI 0.14
- AUPH 0.37
- MACD
- RQI 0.02
- AUPH -0.09
- Stochastic Oscillator
- RQI 94.83
- AUPH 66.51
About RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.